Brokerages Set $45.67 Price Target for Shockwave Medical Inc (NASDAQ:SWAV)

Shares of Shockwave Medical Inc (NASDAQ:SWAV) have been given a consensus broker rating score of 3.00 (Hold) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a hold recommendation.

Analysts have set a 12-month consensus target price of $45.67 for the company and are expecting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also given Shockwave Medical an industry rank of 104 out of 256 based on the ratings given to related companies.

SWAV has been the subject of several research reports. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th. Morgan Stanley restated an “equal weight” rating on shares of KINGFISHER PLC/SH in a research note on Monday, April 1st. Canaccord Genuity raised their price objective on Shockwave Medical from $50.00 to $65.00 and gave the company a “positive” rating in a research note on Tuesday, June 18th. Bank of America set a $10.00 price objective on HEXO and gave the company a “buy” rating in a research note on Thursday, June 13th. Finally, Wells Fargo & Co raised their price objective on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research note on Monday, April 1st.

Shares of SWAV stock traded down $0.45 during trading hours on Monday, hitting $50.38. 204,846 shares of the company were exchanged, compared to its average volume of 434,054. Shockwave Medical has a fifty-two week low of $24.58 and a fifty-two week high of $68.39. The company has a quick ratio of 9.89, a current ratio of 10.37 and a debt-to-equity ratio of 0.11. The company’s 50 day simple moving average is $57.55.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.85). The company had revenue of $7.27 million for the quarter. Analysts anticipate that Shockwave Medical will post -2.74 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SWAV. FMR LLC bought a new stake in Shockwave Medical in the 1st quarter valued at about $117,477,000. Gilder Gagnon Howe & Co. LLC purchased a new position in Shockwave Medical during the 1st quarter valued at about $44,601,000. Redmile Group LLC purchased a new position in Shockwave Medical during the 1st quarter valued at about $10,041,000. Advisory Services Network LLC purchased a new position in Shockwave Medical during the 1st quarter valued at about $26,000. Finally, Marshall Wace LLP purchased a new position in Shockwave Medical during the 1st quarter valued at about $1,016,000. Institutional investors own 45.60% of the company’s stock.

About Shockwave Medical

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Recommended Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Shockwave Medical (SWAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.